Financial restructuring Cue Health is navigating significant profitability and liquidity challenges, including recent workforce reductions and a Chapter 7 bankruptcy filing in 2024. This signals a heightened need for cost-effective, high-value partnerships and flexible commercial models to sustain operations and drive alternative revenue streams.

Diversifying tests The company has shifted from pure COVID-19 testing toward developing multiplex molecular tests (COVID-19, RSV, influenza) under government contracts (BARDA) and federal initiatives. This creates opportunities to position end-to-end diagnostic platforms, regulatory-compliant workflows, and scalable manufacturing partnerships.

Public sector traction BARDA contracts and federal development funding indicate strong government interest in Cue’s diagnostic capabilities. Target opportunities include public health agencies, federal health programs, and co-development or delivery partnerships for point-of-care or at-home molecular tests.

Strategic partnerships New board activity and investment interest, including a collaboration with Tarsadia Investments and leadership changes, point to an openness to strategic financings, co-development deals, and channel partnerships with healthcare providers, payers, or tech platforms to monetize the Cue health ecosystem.

Platform monetization Cue’s device-enabled, lab-quality diagnostics and consumer-facing health information ecosystem offer upsell opportunities into provider networks, digital health integrations, and managed services around testing data, telehealth workflows, and analytics for population health programs.